SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) and raised its twelve month target price from $4.40 to $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday that their lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is now positioned from a regulatory perspective to advance into a pivotal Phase 3 clinical study. In clinical trials performed to date, Tovaxin® has compared favorably to already approved MS therapies, which are multi-billion dollar drugs. Of most significance in our opinion is Tovaxin® ranking ahead of both Copaxone® and Avonex® in Annualized Relapse Rate ("ARR"). ARR is possibly the most clinically relevant endpoint and is the single most important measure by which the FDA evaluates MS drugs for approval." Mr. Silver continued, "Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy, has increased awareness and acceptance for this therapeutic approach."
To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit http://www.vistapglobal.com and complete the research form to gain access to the report.
About Vista Partners:
Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. We are a Registered Investment Advisor in the States of California and Oregon. Our professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Disclaimer & Disclosure:
877.215.4813 or firstname.lastname@example.org
|SOURCE Vista Partners|
Copyright©2010 PR Newswire.
All rights reserved